EU industry cautious about proposed penalties under pharmacovigilance and paediatric frameworks
This article was originally published in SRA
Executive Summary
The European pharmaceutical industry has received cautiously the European Commission's proposal to expand the scope of the EU penalties regulation so that infringement of certain provisions of the Paediatric Regulation and the new pharmacovigilance framework results in financial penalties for drug sponsors1,2.